Table 2.
Summary of the demographic data of patients enrolled in clinical trials testing the efficacy of IL-23, IL-23/12, IL-17, IL-17RA, and TNF-α inhibitors.
| References | Phase | Biologic | Dosing scheme | Endpoint week | Total (n) | Age (years) | Male (%) | Weight (kg) | BMI (kg/m ∧ 2) | Disease duration (years) | % body surface |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Resurface 1 (103) (dosing scheme summary only from part 1) | 3 | Tildrakizumab | 100 mg, week 0, 4 | 12 | 309 | 46.4 | 67 | 88.5 | 29.7 | ||
| Tildrakizumab | 200 mg, week 0, 4 | 12 | 308 | 46.9 | 73 | 88.9 | 30.9 | ||||
| Placebo | 12 | 154 | 47.9 | 65 | 87.5 | 29.6 | |||||
| Resurface 2 (103) (dosing scheme summary only from part 1) | 3 | Tildrakizumab | 100 mg, week 0, 4 | 12 | 307 | 44.6 | 72 | 89.4 | 34.2 | ||
| Tildrakizumab | 200 mg, week 0, 4 | 12 | 314 | 44.6 | 72 | 88.4 | 31.8 | ||||
| Etanercept | 50 mg, week 0, 4 | 12 | 313 | 45.8 | 71 | 88 | 31.6 | ||||
| Placebo | 12 | 156 | 46.4 | 72 | 88.7 | 31.3 | |||||
| Papp et al. (102) | 2b | Tildrakizumab | 5 mg, week 0, 4 | 12 | 42 | 43.2 | 74 | 28.9 | |||
| Tildrakizumab | 25 mg week 0, 4 | 12 | 92 | 46.3 | 65 | 28.5 | |||||
| Tildrakizumab | 100 mg week 0.4 | 12 | 89 | 45.5 | 85 | 29 | |||||
| Tildrakizumab | 200 mg week 0, 4 | 12 | 86 | 43.2 | 76 | 28.5 | |||||
| Placebo | 12 | 46 | 45.9 | 83 | 29.5 | ||||||
| Kopp et al. (101) | 1 | Tildrakizumab | 3 mg/kg–weeks 0, 4 | 28 | 7 | 52.7 | 100 | 90.27 | |||
| Tildrakizumab | 10 mg/kg–weeks 0, 4 | 28 | 6 | 46.2 | 67 | 94.25 | |||||
| Placebo | 28 | 20 | 45.5 | 80 | 102.46 | ||||||
| Voyage 1 (72) | 3 | Guselkumab | 100 mg–week 0, 4 | 16 | 329 | 43.9 | 72.9 | 29.7 | 17.9 | 28.3 | |
| Placebo | 16 | 174 | 44.9 | 68.4 | 28.9 | 17.6 | 25.8 | ||||
| Voyage 2 (74) | 3 | Guselkumab | 100 mg–week 0, 4 | 16 | 496 | 43.7 | 70.4 | 29.6 | 17.9 | 28.5 | |
| Placebo | 16 | 248 | 43.3 | 69.8 | 29.6 | 17.9 | 28 | ||||
| UltIMMa-1 (79) | 3 | Risankizumab | 150 mg–week 0, 4 | 16 | 304 | 48.3 | 70 | 87.8 | 26.2 | ||
| Placebo | 16 | 102 | 49.3 | 77 | 88.8 | 27.9 | |||||
| UltIMMa-2 (79) | 3 | Risankizumab | 150 mg–week 0, 4 | 16 | 294 | 46.2 | 69 | 92.2 | 26.2 | ||
| Placebo | 16 | 98 | 46.3 | 68 | 92.2 | 23.9 | |||||
| Reich et al. (82) | 2 | Mirikizumab | 100 mg–week 0, 8 | 16 | 51 | 46 | 69 | 86.4 | 18.6 | 26.5 | |
| Mirikizumab | 300 mg–week 0, 8 | 16 | 51 | 47.5 | 71 | 87.9 | 18.1 | 21.3 | |||
| Placebo | 16 | 52 | 46 | 81 | 89.1 | 18 | 26.4 | ||||
| Phoenix-1 (51) | 3 | Ustekinumab | 90 mg–week 0, 4 | 12 | 256 | 46.2 | 67.6 | 93.8 | 19.6 | 25.2 | |
| Placebo | 12 | 255 | 44.8 | 71.8 | 94.2 | 20.4 | 27.7 | ||||
| Phoenix-2 (52) | 3 | Ustekinumab | 90 mg–week 0, 4 | 12 | 411 | 46.6 | 66.7 | 91.5 | 20.3 | 27.1 | |
| Placebo | 12 | 410 | 47 | 69 | 91.1 | 20.8 | 26.1 | ||||
| FIXTURE (135) | 3 | Secukinumab | 150 mg–weeks 0–4 then every 4 weeks thereafter | 12 | 327 | 45.4 | 72.2 | 83.6 | 17.3 | 34.5 | |
| Secukinumab | 300 mg–weeks 0–4 then every 4 weeks thereafter | 12 | 327 | 44.5 | 68.5 | 83 | 15.8 | 34.3 | |||
| Placebo | 12 | 326 | 44.1 | 72.7 | 82 | 16.6 | 35.2 | ||||
| Etanercept | 50 mg–weeks 0–4 then every 4 weeks thereafter | 12 | 326 | 43.8 | 71.2 | 84.6 | 16.4 | 33.6 | |||
| UNCOVER-1 (123) | 3 | Ixekizumab | 160 mg × 1, 80 mg (q2w) | 12 | 433 | 45 | 67.2 | 92 | 20 | 27 | |
| Ixekizumab | 160 mg × 1, 80 mg (q4w) | 12 | 432 | 46 | 66.9 | 92 | 19 | 28 | |||
| Placebo | 12 | 431 | 46 | 70.3 | 92 | 20 | 27 | ||||
| AMAGINE-1 (136) | 3 | Brodalumab | 140 mg q2w | 12 | 219 | 46 | 74 | 90.6 | 19 | 27.4 | |
| Brodalumab | 210 mg q2w | 12 | 222 | 46 | 73 | 91.4 | 20 | 25.1 | |||
| Placebo | 12 | 220 | 47 | 73 | 90.4 | 21 | 26.9 | ||||
| BE ABLE 1 (137) | 2b | Bimekizumab | 160 mg q4w | 12 | 40 | 43.4 | 65.1 | 91.6 | 15.9 | 24 | |
| Bimekizumab | 320 mg q4w | 12 | 43 | 42.6 | 74.4 | 86.9 | 15.9 | 24 | |||
| Placebo | 12 | 42 | 46.7 | 59.5 | 88.8 | 15 | 25.5 | ||||
| EXPRESS II (138) | Infliximab | 5 mg/kg | 14 | 314 | 44.5 | 65 | 92.2 | 19.1 | 28.7 | ||
| Placebo | 14 | 208 | 44.4 | 69.2 | 91.1 | 17.8 | 28.4 | ||||
| REVEAL (139) | 3 | Adalimumab | 40 mg q2w | 15 | 814 | 44.1 | 67.1 | 92.3 | 18.1 | 25.8 | |
| Placebo | 15 | 398 | 45.4 | 64.6 | 94.1 | 18.4 | 25.6 | ||||
| CIMPACT (140) | 3 | Certolizumab pegol | 200 mg q2w | 16 | 165 | 46.7 | 68.5 | 89.7 | 19.5 | 28.1 | |
| Placebo | 16 | 57 | 46.5 | 59.6 | 93.7 | 18.9 | 24.3 | ||||
| GO-VIBRANT (141) | 3 | Golimumab | 2 mg/kg, weeks 0, 4 then every 8 weeks thereafter | 16 | 241 | 45.7 | 53.1 | 6.2 | |||
| Placebo | 16 | 239 | 46.7 | 50.6 | 5.3 |